Navigation Links
GenVec Announces Update of Safety and Efficacy Data from Pivotal,Phase II/III PACT Study of TNFerade at ASCO

Ferade(TM), is currently in a pivotal Phase II/III study (PACT) in locally advanced pancreatic cancer; Phase II studies are in progress in rectal cancer and melanoma; and Phase I/II studies are in progress in head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and seasonal and pandemic flu. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Preliminary clinical trial data cannot be considered predictive of final trial outcome. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Excha
'"/>




Page: 1 2 3 4

Related medicine technology :

1. GenVec Presents Research on New Ad35 Adenovector at ARVO
2. GenVec Announces New Research at AACR on Selectivity and Mechanism of Action of TNF-Based Anti-Cancer Therapy
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron Pharmaceuticals, ... SAN and NYSE: SNY ) today announced ... in people with hypercholesterolemia met their primary efficacy endpoint ... lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo ... targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... -- DigiPath, Inc. (OTCBB and OTCQB: DIGP), a digital pathology ... and education markets, announced today that has been no ... disclosed or, to its knowledge, any other reason to ... "We have noticed unusual price and volume increases for ... Steve Barbee , CEO of DigiPath. "While we ...
(Date:7/30/2014)... July 30, 2014  Packaging Coordinators, Inc. (PCI) is ... to acquire Penn Pharmaceutical Services Limited (Penn Pharma). Penn Pharma ... in the United Kingdom and ... and Tokyo , Japan. Penn ... Clinical and Commercial dosage form manufacturing, as well as ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5
(Date:7/30/2014)... Of the many sub-groups of cells jockeying for ... not be those that can proliferate the fastest, researchers ... in an advance online publication of the journal ... the treatment of cancer with precision medicines, the study ... are truly driving the tumor,s growth and metastasis and ...
(Date:7/30/2014)... July 30, 2014 Everyone knows that the ... basically everyone. Whether people are looking for something to buy, ... a dentist, the internet is pretty much always going to ... Dental in Lauderdale Florida is so happy to announce the ... web presence into the modern age. Whether a person wants ...
(Date:7/30/2014)... Dallas, Texas (PRWEB) July 30, 2014 ... provides key market data on the North America Contrast ... of US dollars, and volume (in units) and average ...     CT Injectors ,     Interventional Cardiology/Angio Injectors ... medium (or contrast agent) is a substance used to ...
(Date:7/30/2014)... (WAVES) conference is coming to Fairfield, Iowa,s Maharishi University ... August 3. To watch the main plenary talks, visit ... such a large and diverse group of Vedic scholars ... relevance of ancient Vedic knowledge in today,s world. Topics ... and reflections on the various Vedic texts. , The ...
(Date:7/30/2014)... Naomi Fried, PhD, and Alexis Gilroy, ... of the American Telemedicine Association (ATA). The ... a mission to promote professional, ethical and equitable ... technology. , “Both Naomi Fried and Alexis Gilroy, ... and are well known experts in their respective ...
Breaking Medicine News(10 mins):Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 3Health News:Sierra Dental Releases New Website For Fort Lauderdale Residents 2Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 2Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 3Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 4Health News:Vedic living in a modern world: International conference at Maharishi University 2Health News:Vedic living in a modern world: International conference at Maharishi University 3Health News:American Telemedicine Association Welcomes Two New Members to the Board of Directors 2
... The Justice Department,today announced that it has reached ... is headquartered in Southfield, Mich., under the,Americans with ... Weight,Loss Clinic refused to serve a prospective client ... of today,s agreement, Medical Weight Loss Clinic will,provide ...
... to announce the arrival of newly FDA-approved Evolence®--the latest injectable ... beauty treatments. EVOLENCE® utilizes highly-purified porcine Type I collagen, regarded ... identical similarity to human collagen. , ... ...
... G.,Rendell today issued an executive order regarding the ... after the law,authorizing its operation expired on June ... when PHC4 was allowed to "sunset",by the General ... The Rendell administration is committed to creating ...
... serve a distinct advantage on, the road to recovery, said Carl ... ... July 8 The Mariners Inn shelter and treatment,center in downtown Detroit is ... chief operating officer., "Both Jim and David are outstanding leaders in the ...
... Reductions in Iron Blood Levels Associated with Decreased Cancer Risk ... peripheral arterial disease who participated in a randomized controlled trial ... had a reduced incidence of cancer relative to men in ... studies have suggested that lower levels of iron in the ...
... Act yet to show drop-off in access predicted by ... patients have not lost access to care despite federal ... recent years, a new report finds. , Critics feared ... would make treatment more difficult, but investigators from the ...
Cached Medicine News:Health News:Justice Department Reaches Settlement Agreement With Medical Weight Loss Clinic 2Health News:Move Over, Popular Beauty Fillers--Here Comes Evolence 2Health News:Move Over, Popular Beauty Fillers--Here Comes Evolence 3Health News:Governor Rendell Issues Executive Order Regarding Pennsylvania Health Care Cost Containment Council 2Health News:Governor Rendell Issues Executive Order Regarding Pennsylvania Health Care Cost Containment Council 3Health News:Mariners Inn Announces New Executive Leadership 2Health News:Also in the July 8 JNCI 2Health News:Also in the July 8 JNCI 3Health News:Also in the July 8 JNCI 4Health News:Cancer Care Unaffected by Doctor Reimbursement Changes 2
... Single Use reloadable linear stapler for resection, ... ,The Auto Suture™ MULTIFIRE GIA™ 60 and ... GIA™ 60 and 80 single use loading ... 60 knifeless single use surgical stapler with ...
... Loading Units With Titanium Staples ... (Single Use Reloadable Staplers With ... ILA™ 75 single-use stapler, anastomotic ... in the resection, transection, and/or ...
... The PROXIMATE HCS Procedure for Prolapse ... rows of titanium staples in 33mm diameter ... anal canal for transection and resection of ... the surgical treatment of hemorrhoidal disease. The ...
The Reusable Purse String Clamp is intended for use in the mechanical construction of a purse string suture. The clamp can be used on any part of the gastrointestinal tract except the esophagus....
Medicine Products: